Skip to main content

Pancreatic Cancer: Drugs

Question for Department of Health

UIN 217091, tabled on 3 December 2014

To ask the Secretary of State for Health, what progress he has made on the decision-making process on whether the most effective medicines will continue to be made available to patients with pancreatic cancer on the NHS.

Answered on

8 December 2014

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies. NICE has been asked to appraise a number of pancreatic cancer drugs and commissioners will continue to be legally required to fund treatments recommended by NICE technology appraisal guidance.

Decisions on the drugs made available through the Cancer Drugs Fund are a matter for NHS England’s Cancer Drugs Fund panel. The standard operating procedures for the Fund, which outline the decision-making process the panel follows is available at:

We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.